226 related articles for article (PubMed ID: 35987486)
21. Biologics in the treatment of asthma in children and adolescents.
Bacharier LB; Jackson DJ
J Allergy Clin Immunol; 2023 Mar; 151(3):581-589. PubMed ID: 36702649
[TBL] [Abstract][Full Text] [Related]
22. Biologics for chronic rhinosinusitis.
Chong LY; Piromchai P; Sharp S; Snidvongs K; Philpott C; Hopkins C; Burton MJ
Cochrane Database Syst Rev; 2020 Feb; 2(2):CD013513. PubMed ID: 32102112
[TBL] [Abstract][Full Text] [Related]
23. Smaller Differences in the Comparative Effectiveness of Biologics in Reducing Asthma-Related Hospitalizations Compared With Overall Exacerbations.
Akenroye A; Marshall J; Simon AL; Hague C; Costa R; Jamal-Allial A; McMahill-Walraven CN; Haffenreffer K; Han A; Wu AC
J Allergy Clin Immunol Pract; 2024 Jun; 12(6):1568-1574.e2. PubMed ID: 38431251
[TBL] [Abstract][Full Text] [Related]
24. Comparative Impact of Asthma Biologics: A Nationwide US Claim-Based Analysis.
Al-Shaikhly T; Norris MR; Dennis EH; Liu G; Craig TJ
J Allergy Clin Immunol Pract; 2024 Jun; 12(6):1558-1567. PubMed ID: 38423294
[TBL] [Abstract][Full Text] [Related]
25. New perspectives of childhood asthma treatment with biologics.
Just J; Deschildre A; Lejeune S; Amat F
Pediatr Allergy Immunol; 2019 Mar; 30(2):159-171. PubMed ID: 30444939
[TBL] [Abstract][Full Text] [Related]
26. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
[TBL] [Abstract][Full Text] [Related]
27. Lower Use of Biologics for the Treatment of Asthma in Publicly Insured Individuals.
Akenroye AT; Heyward J; Keet C; Alexander GC
J Allergy Clin Immunol Pract; 2021 Nov; 9(11):3969-3976. PubMed ID: 33556592
[TBL] [Abstract][Full Text] [Related]
28. Comparison of omalizumab and mepolizumab treatment efficacy in patients with atopic and eosinophilic "Overlap" severe asthma: Biological agent preference in atopic-eosinophilic severe asthma.
Tepetam FM; Akyildiz AB; Özden Ş; Örcen C; Yakut T; Atik Ö
Medicine (Baltimore); 2023 May; 102(18):e33660. PubMed ID: 37144999
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and Safety of Biologics for Chronic Rhinosinusitis With Nasal Polyps.
Koski RR; Hill L; Taavola K
J Pharm Technol; 2022 Oct; 38(5):289-296. PubMed ID: 36046351
[No Abstract] [Full Text] [Related]
30. Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma.
Porsbjerg CM; Menzies-Gow AN; Tran TN; Murray RB; Unni B; Audrey Ang SL; Alacqua M; Al-Ahmad M; Al-Lehebi R; Altraja A; Belevskiy AS; Björnsdóttir US; Bourdin A; Busby J; Canonica GW; Christoff GC; Cosio BG; Costello RW; FitzGerald JM; Fonseca JA; Hansen S; Heaney LG; Heffler E; Hew M; Iwanaga T; Jackson DJ; Kocks JWH; Kallieri M; Bruce Ko HK; Koh MS; Larenas-Linnemann D; Lehtimäki LA; Loukides S; Lugogo N; Maspero J; Papaioannou AI; Perez-de-Llano L; Pitrez PM; Popov TA; Rasmussen LM; Rhee CK; Sadatsafavi M; Schmid J; Siddiqui S; Taillé C; Taube C; Torres-Duque CA; Ulrik C; Upham JW; Wang E; Wechsler ME; Bulathsinhala L; Carter V; Chaudhry I; Eleangovan N; Hosseini N; Rowlands MA; Price DB; van Boven JFM
J Allergy Clin Immunol Pract; 2022 May; 10(5):1202-1216.e23. PubMed ID: 34990866
[TBL] [Abstract][Full Text] [Related]
31. Pragmatic Clinical Perspective on Biologics for Severe Refractory Type 2 Asthma.
Chan R; RuiWen Kuo C; Lipworth B
J Allergy Clin Immunol Pract; 2020; 8(10):3363-3370. PubMed ID: 32673880
[TBL] [Abstract][Full Text] [Related]
32. Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma.
Bateman ED; Khan AH; Xu Y; Guyot P; Chao J; Kamat S; Rowe P; Burnett H; Msihid J; Weinreich D; Pavord ID
Respir Med; 2022 Jan; 191():105991. PubMed ID: 35090688
[TBL] [Abstract][Full Text] [Related]
33. Immunobiologic treatments for severe asthma, atopic dermatitis, and chronic urticaria.
Chiarella SE
Allergy Asthma Proc; 2019 Nov; 40(6):485-489. PubMed ID: 31690400
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness analysis of dupilumab among patients with oral corticosteroid-dependent uncontrolled severe asthma in Japan.
Tohda Y; Matsumoto H; Miyata M; Taguchi Y; Ueyama M; Joulain F; Arakawa I
J Asthma; 2022 Nov; 59(11):2162-2173. PubMed ID: 34752208
[TBL] [Abstract][Full Text] [Related]
35. Asthma Management in Adults.
Busse WW; Castro M; Casale TB
J Allergy Clin Immunol Pract; 2023 Jan; 11(1):21-33. PubMed ID: 36283607
[TBL] [Abstract][Full Text] [Related]
36. Mapping knowledge structure and research of the biologic treatment of asthma: A bibliometric study.
Sun J; Bai S; Zhao J; Li D; Ma X; Ma L; Su X
Front Immunol; 2023; 14():1034755. PubMed ID: 36845128
[TBL] [Abstract][Full Text] [Related]
37. Biologics for the Use in Chronic Spontaneous Urticaria: When and Which.
Maurer M; Khan DA; Elieh Ali Komi D; Kaplan AP
J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1067-1078. PubMed ID: 33685605
[TBL] [Abstract][Full Text] [Related]
38. The effect of maternal exposure to psychosocial job strain on pregnancy outcomes and child development.
Larsen AD
Dan Med J; 2015 Feb; 62(2):. PubMed ID: 25634513
[TBL] [Abstract][Full Text] [Related]
39. When sequential use of mepolizumab and dupilumab in a severe atopic eosinophilic asthmatic questions the role of eosinophils in mediating the clinical expression of the disease: a case report.
Sabbe M; Schleich F; Janssens P; Louis R
J Med Case Rep; 2024 Jan; 18(1):63. PubMed ID: 38291489
[TBL] [Abstract][Full Text] [Related]
40. Clinical effects and immune modulation of biologics in asthma.
Harada N; Ito J; Takahashi K
Respir Investig; 2021 Jul; 59(4):389-396. PubMed ID: 33893067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]